2018 Agenda

PMPRB Framework modernization is underway with significant changes pending to both the Patented Medicine’s Regulations and PMPRB Pricing Guidelines. Gather insights on:

• The latest developments on Health Canada’s proposal to add new factors to the PMPRB’s price ceiling setting process
• How the PMPRB might operationalize these factors as part of its new risk-based approach to price regulation
• What the changes will mean for pharmaceutical companies

Discover what regulatory changes can mean to your market access strategy.

Changes to the Patented Medicines Regulations and PMPRB Pricing Guidelines mean the adoption of new strategies for market access professionals. After PMPRB’s keynote, discuss strategies to:

• Develop market access strategies in accordance with regulatory changes
• Address Health Canada’s proposal with regard to the PMPRB’s price ceilings
• Adopt PMPRB’s new risk-based approach to price regulation

Develop new market access strategies to adapt to regulatory changes.

The Regulatory Review of Drugs and Devices (R2D2) initiative changes how you work. Review the objectives of this initiative to improve access to treatment. Stay up-to-date on:

• Expanded collaboration with health partners
• More timely access to drugs and devices
• Enhanced use of real word data

Analyse the R2D2 initiative to enhance access to treatment.

Governments, payers and healthcare’s other stakeholders increasingly look to incorporate data to support decision-making. Explore innovation in Real-World Evidence to improve the value, efficacy and impact of medicines. Take away strategies to:

• Enhance efficacy of your medicines on individual patient outcomes
• Evaluate the impact on the health of the overall populations
• Partner with your stakeholders to access data

Prove and improve the value, efficacy and impact of your medicines with RWE.

Regional health authorities are working to improve alignment with public drug plans and utilize the best available evidence when reviewing hospital only drugs. Clarify how Alberta approaches DTC processes, what information about system costs AHS uses to make decisions and evaluate some of the work that has been done to date to improve your market access strategy. Gain insights to:

• Align with the Alberta Drug Benefit List
• Improve Market Access around DTC Processes
• Understand how RFPs are done

Evaluate the evolution of decision-making at the regional level and its effects on your organization.

Reconciling the urgency of patient need with a thorough HTA process is a growing a challenge. Explore what patients expect from you to improve patient outcomes. Gain insights to:

• What patient centricity means to the end user (the patient)
• Refine your stakeholder mapping
• Advance your stakeholder engagement process

Ensure the patients are at the centre of your strategic planning.

There is a lot of buzz around harnessing historic trends and patterns in patient data - is it hype or reality? Many wonder if it will impact PSP design and implementation and whether patients will benefit. Take away a plan to understand:

• What is predictive analytics in the PSP environment?
• Is it actionable?
• What is the impact on patient engagement?
• Can informed analytics impact patient outcomes?

Understand how predictive analytics in patient support could help your organization.

Complying with Provincial expectations for product listing agreements is critical to your market access strategy. Ensure you meet the needs of key provinces to get your product to market. Gain practical tips to:

• Get your product to market faster
• Clarify upcoming changes to PLAs
• Review your value proposition

Gain practical insights on how to list your drug with a province.

The private payer landscape is undergoing significant changes that will impact patient access and how medications are reimbursed. Strengthen your market access strategy with insights into emerging trends in the private payer landscape. Source critical information to:

• Assess trends among large employers
• Revise changes in industry leadership and emerging partnerships
• Review the solutions plan sponsors are considering

Integrate the employer’s outlook into your market access strategies.

Small markets can impede the development of orphan drugs, but collaboration can alleviate some restraints. Build partnerships to develop your new products and secure revenue opportunities. Build a roadmap to:

• Explore funding and joint research opportunities
• Gather inputs from patients
• Optimize your company’s ROI in a small market

Work with your stakeholders to increase patient access to treatments.